Follow-The-Filings

Security · featured owners

ZNTL Zentalis Pharmaceuticals Inc.

COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.6%
  • $7M

Who owns this now

Largest portfolio weights among featured holders · max 0.6% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman 0.62%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 0.62% Hold 1,412,656 $7M history

1 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $67.42M $0.00
Net income -$292.19M -$165.84M -$137.06M
Net margin * — -246.0% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $496.72M $386.07M $253.19M
Total non-current assets * $54.97M $44.27M $35.78M
Total assets $551.69M $430.34M $288.97M
Total current liabilities $69.37M $52.72M $36.56M
Total non-current liabilities * $44.93M $40.43M $36.2M
Total equity $437.28M $337.19M $216.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$207.82M -$170.86M -$125.25M
Cash from investing -$44.46M $176.56M $131.62M
Cash from financing $237.3M $108,000 -$4.28M
Net change in cash -$14.98M $5.81M $2.09M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders